Investor Information: Press Releases

iCo trades on the TSX Venture Exchange under the symbol “ICO” and the OTCQB the symbol “ICOTF”

News and Releases · Financial Information · Events and Presentations · Articles

 

Title Date
iCo Therapeutics Inc.: Carc – Online Pharmacy Services and Canadian Drugs July 18, 2024
iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- 019 on SARS-CoV-2 March 15, 2021
iCo Therapeutics Inc. Announces Warrant Exercises March 11, 2021
iCo Therapeutics Inc. Proposes to Re-Price Warrants January 11, 2021
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical December 31, 2020
iCo Therapeutics Announces Third Quarter 2020 Financial Results November 24, 2020
iCo Therapeutics Announces Option Grants October 26, 2020
iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020 October 21, 2020
iCo Therapeutics Announces Second Quarter 2020 Financial Results August 31, 2020
iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases Journal July 30, 2020
iCo Therapeutics Announces First Quarter 2020 Financial Results July 13, 2020
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion Updates June 22, 2020
iCo Therapeutics Inc. Announces Q1 Interim Filing Update May 29, 2020
iCo Therapeutics Announces 2019 Year End Financial Results May 19, 2020
iCo Therapeutics Inc. Announces Annual Filing Update April 27, 2020
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research April 15, 2020
iCo Therapeutics Announces Leadership Changes March 9, 2020
iCo Therapeutics Successfully Concludes Phase 1b Clinical Study Announces Positive Primary End Point for Oral Amphotericin B February 25, 2020
iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up February 10, 2020
iCo Therapeutics Inc. Proposes to Re-Price Warrants January 11, 2020
iCo Therapeutics Announces Option Grants January 10, 2020